

Genevieve M Weir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5403948/publications.pdf>

Version: 2024-02-01

22
papers

594
citations

687363

13
h-index

752698

20
g-index

22
all docs

22
docs citations

22
times ranked

988
citing authors

#	ARTICLE	IF	CITATIONS
1	Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. <i>Onc Immunology</i> , 2015, 4, e1026529.	4.6	79
2	First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. <i>Journal of Translational Medicine</i> , 2012, 10, 156.	4.4	71
3	Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines. <i>Cancers</i> , 2011, 3, 3114-3142.	3.7	64
4	Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax®. <i>Journal of Translational Medicine</i> , 2007, 5, 20.	4.4	43
5	A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study. <i>Journal of Infectious Diseases</i> , 2018, 218, 378-387.	4.0	39
6	A liposome-based platform, VacciMax®, and its modified water-free platform DepoVax®, enhance efficacy of in vivo nucleic acid delivery. <i>Vaccine</i> , 2010, 28, 6176-6182.	3.8	34
7	Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax® encapsulated CTL/T helper peptides. <i>Journal of Translational Medicine</i> , 2007, 5, 26.	4.4	33
8	Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. <i>Onc Immunology</i> , 2014, 3, e953407.	4.6	32
9	A Novel Breast/Ovarian Cancer Peptide Vaccine Platform That Promotes Specific Type-1 but not Treg/Tr1-type Responses. <i>Journal of Immunotherapy</i> , 2010, 33, 250-261.	2.4	30
10	Using MRI cell tracking to monitor immune cell recruitment in response to a peptide-based cancer vaccine. <i>Magnetic Resonance in Medicine</i> , 2018, 80, 304-316.	3.0	30
11	Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. , 2016, 4, 68.		27
12	Clearance of depot vaccine SPIO-labeled antigen and substrate visualized using MRI. <i>Vaccine</i> , 2014, 32, 6956-6962.	3.8	22
13	Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo. <i>PLoS ONE</i> , 2017, 12, e0180073.	2.5	22
14	Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control. <i>Journal of Biomedical Science</i> , 2018, 25, 7.	7.0	19
15	Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal <i>Bacillus anthracis</i> spore inhalation challenge. <i>Npj Vaccines</i> , 2019, 4, 6.	6.0	12
16	Using lymph node swelling as a potential biomarker for successful vaccination. <i>Oncotarget</i> , 2016, 7, 35655-35669.	1.8	11
17	Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 15048.	4.1	7
18	Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2007-2017.	3.3	7

#	ARTICLE	IF	CITATIONS
19	Quantitative MRI cell tracking of immune cell recruitment to tumors and draining lymph nodes in response to anti-PD-1 and a DPX-based immunotherapy. <i>Oncolmmunology</i> , 2020, 9, 1851539.	4.6	6
20	Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 59-66.	3.3	4
21	Generation of highly activated, antigen-specific tumor-infiltrating CD8 ⁺ T cells induced by a novel T cell-targeted immunotherapy. <i>Oncolmmunology</i> , 2020, 9, 1782574.	4.6	2
22	Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in aHPV16 E7-expressing C3 tumour model. <i>Scientific Reports</i> , 2021, 11, 4502.	3.3	0